Nitric oxide confers therapeutic activity to dendritic cells in a mouse model of melanoma by C. Perrotta et al.
[CANCER RESEARCH 64, 3767–3771, June 1, 2004]
Advances in Brief
Nitric Oxide Confers Therapeutic Activity to Dendritic Cells in a Mouse
Model of Melanoma
Cristiana Perrotta,1,2 Sestina Falcone,3,4 Annalisa Capobianco,2 Annalisa Camporeale,2 Clara Sciorati,2
Clara De Palma,1,2 Addolorata Pisconti,2 Patrizia Rovere-Querini,2 Matteo Bellone,2 Angelo A. Manfredi,2 and
Emilio Clementi2,3,4
1Department of Pharmaco-Biology, University of Calabria, Rende; 2Vita-Salute University and DIBIT H San Raffaele Scientific Institute, Milan; 3Department of Preclinical
Sciences, LITA Vialba, L. Sacco Hospital, University of Milano, Milan; and 4E. Medea Scientific Institute, Bosisio Parini, Italy
Abstract
Susceptibility of dendritic cells (DCs) to tumor-induced apoptosis re-
duces their efficacy in cancer therapy. Here we show that delivery within
exponentially growing B16 melanomas of DCs treated ex vivo with nitric
oxide (NO), released by the NO donor (z)-1-[2-(2-aminoethyl)-N-(2-am-
monioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO), significantly re-
duced tumor growth, with cure of 37% of animals. DETA-NO-treated
DCs became resistant to tumor-induced apoptosis because DETA-NO
prevented tumor-induced changes in the expression of Bcl-2, Bax, and
Bcl-xL; activation of caspase-9; and a reduction in the mitochondrial
membrane potential. DETA-NO also increased DC cytotoxic activity
against tumor cells and DC ability to trigger T-lymphocyte proliferation.
All of the effects of DETA-NO were mediated through cGMP generation.
NO and NO-generating drugs may therefore be used to increase the
anticancer efficacy of DCs.
Introduction
The function of dendritic cells (DCs), professional antigen-present-
ing cells involved in the initiation of immune responses, is impaired
in tumors (1). This is due to a reduced ability of DCs to migrate to
lymphoid organs and prime immune responses, and to tumor-induced
apoptotic death of DCs, which correlates to the grade of the tumors
and their prognosis (1–5). Indeed, preclinical studies and clinical trials
have shown that intratumor delivery of DCs, modified ex vivo to
increase their function, is a suitable therapeutic approach to limit
tumor progression (6–8), whereas strategies to specifically enhance
resistance of DCs to tumor-induced apoptosis have been studied to
only a limited extent (5, 9–12).
A candidate molecule to improve DC ability to withstand the toxic
tumor environment is nitric oxide (NO). Physiological concentrations
of NO exert antiapoptotic effects in many cells (13). All of the specific
events mediating tumor-induced apoptosis of DCs, including activa-
tion of caspases, reduction of the mitochondrial membrane potential
and of the expression/activity of antiapoptotic Bcl-2, and increased
expression of proapoptotic Bax (4, 5, 10, 14), were shown to be
targets of NO, although in other cell types (13, 15). In addition, NO
increases DC cytotoxic, endocytic, and antigen-presenting functions
(16–18).
In this study we show that the treatment ex vivo of DCs with a pulse
of the NO donor (z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amin-
o]diazen-1-ium-1,2-diolate (DETA-NO) before delivery within a s.c.-
growing B16 mouse melanoma confers persistent antitumor action to
DCs. We also provide the mechanisms responsible for the effect of
NO.
Materials and Methods
Animals. Female C57BL/6 (H-2b) and BALB/c (H-2d) mice, 6–8 weeks of
age, were purchased from Charles River Laboratories (Calco, Italy) and treated
in accordance with the European Community guidelines and with the approval
of the Institutional Ethical Committee.
Cells. B16-F1 (H-2b) melanoma cells were cultured as described previously
(14). The culture-conditioned medium (B16SN) was prepared by culturing
1  106 cells in 20 ml of medium for 4 days and was used at a final
concentration of 20% (14).
DCs were obtained from mouse bone marrow precursors, cultured as
described previously (19). DCs were characterized by flow cytometry meas-
uring plasma membrane expression of MHC class I and II, CD11c, CD80,
CD83, and CD86 (17). The purity of DCs was in all experiments no less than
80%. The remaining CD11c-negative cells mostly comprised macrophages and
lymphocytes. cGMP concentrations were measured by a radioimmunoassay
(18) in samples (1  106 cells in 0.5 mM phosphodiesterase inhibitor 3-isobu-
tyl-1-methyl xanthine) treated for 30 min with or without DETA-NO in the
presence or absence of H-(1,2,4)-oxadiazolo[4,3-]quinoxalin-1-one (ODQ;
both from Alexis Italia, Florence, Italy; Ref. 18).
Intratumoral DC Injection. C57BL/6 mice (five animals/group) received
1  105 B16-F1 cells, i.e., 10-fold the minimum tumorigenic dose (19), s.c. in
the lower right flank on day 0 (19). Tumors reached the appropriate size (10
mm2) after 6 days. DCs (1 106) or vehicle (PBS) were injected in the tumors
on day 6, 12, 18, and 24, and tumor growth was monitored. Mice were
sacrificed when theirs tumors reached 15 mm in size on either diameter. Mice
received injections of vehicle; untreated DCs, DETA-NO-treated DCs, 8-Br-
cGMP-treated DCs, and DCs treated with DETA-NO and ODQ. Treatments of
DCs were for 2 h, and the compounds were removed by washing before
injection. To reveal injected DCs at tumor sites, we labeled the DCs with
fluorescent dye the 5-chloromethylfluorescein (CMFDA; 2 M; Molecular
Probes, Leiden, the Netherlands) for 30 min at 37°C (19). Tumors were
collected 24 and 72 h after DC injection. Single-cell suspensions (19) were
labeled with a phycoerythrin-conjugated anti-CD11c monoclonal antibody and
analyzed by flow cytometry.
Measurements of Apoptosis. The mitochondrial membrane potential and
DNA content were analyzed by flow cytometry in DCs (1  106 cells/sample)
stained with the potential-sensitive fluorescent dye tetramethylrhodamine ethyl
ester (500 nM; Molecular Probes; Ref. 20) or propidium iodide (50 g/ml in
permeabilized DCs; Ref. 15), respectively. We assessed caspase-9 activity in
DC lysates as described previously (15), measuring the cleavage of the
fluorogenic caspase-9 substrate Ac-LEHD-7 amino-4-trifluoromethyl couma-
rin with a Perkin-Elmer LS50 fluorometer. Western blot analyses were carried
out on 50 g of DC lysates (17). Relevant bands were immunolabeled with
rabbit polyclonal primary antibodies specific for either Bcl-xL or Bax (Cell
Signaling Technology, Beverly, CA) or mouse monoclonal antibodies recog-
nizing Bcl-2 (Upstate Biotechnology, Lake Placid, NY), followed by incuba-
tion with horseradish peroxidase-conjugated goat polyclonal antirabbit or
antimouse IgGs (Transduction Laboratories, Lexington, KY). Immunoreactive
bands were visualized by the enhanced chemiluminescence procedure and
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quantified by microdensitometry using a Molecular Dynamics Imagequant
apparatus (17).
Measurements of DC Functions. For mixed-lymphocyte reactions, DCs
from C57BL/6 mice were irradiated (2500 rad) and cocultured at different
ratios with spleen-derived BALB/c lymphocytes (105 cells/well; Ref. 14).
Incorporation of methyl-[3H]thymidine by T cells was evaluated at day 5 (18).
Cytotoxic activity of DCs was assessed by measuring the specific 51Cr release
in a standard assay in which serial dilutions of DCs were mixed with 3000
51Cr-labeled B16-F1 cells or syngeneic splenocytes (19).
All solutions used were endotoxin free as determined by the Limulus test
(PBI, Milan, Italy).
Statistical Analysis. All results are expressed as means  SE, and n
represents the number of individual experiments. Statistical analyses were
performed with Student’s t test and the log-rank statistic. All data were
considered statistically significant at P  0.05. In the figure panels, , , and
 indicate P  0.05, P  0.01, and P 0.001, respectively.
Results
Treatment with NO Enhances DC Antitumor Activity in Vivo
and Their Persistence at the Tumor Site through a cGMP-De-
pendent Pathway. DCs were treated in the presence or absence of
the NO donor DETA-NO (10 M), the cell permeable analog of
cGMP 8-Br-cGMP (3 mM), or DETA-NO combined with ODQ (1
M), a selective guanylate cyclase inhibitor that prevents NO-depen-
dent cGMP generation (18). DETA-NO at 10 M yielded a steady-
state concentration of 11  0.1 nM NO (n  4) as measured by a NO
electrode (18). All treatments were for 2 h, and agents were removed
after treatments. Vehicle or the DC preparations were injected intra-
tumorally in s.c.-growing B16 melanomas 6, 12, 18, and 24 days after
injection of B16-F1 cells (1 105 cells; Fig. 1A). In the group of mice
receiving untreated DCs, tumor growth was slightly delayed com-
pared with vehicle-injected mice. All of the animals eventually died
because of the tumor. Conversely, in the groups receiving injections
of DETA-NO- or 8-Br-cGMP-treated DCs, tumor growth was signif-
icantly reduced (Fig. 1A), and animal survival was 33  4 and
37  3%, respectively (P  0.001 versus untreated DCs; n  6; Fig.
1B). Tumor regression was observed in all surviving animals. Injec-
tion of DCs treated with DETA-NO together with the guanylate
cyclase inhibitor ODQ neither inhibited tumor growth nor cured any
animals.
To evaluate their intratumor survival, we stained DCs with the dye
CMFDA (19) before their ex vivo treatment and injection into tumors.
Tumors were recovered 24 and 72 h after injection, and cells were
dispersed and analyzed by flow cytometry after staining for the DC
marker CD11c. Treatment ex vivo of DCs with DETA-NO or 8-Br-
cGMP resulted in the recovery of significantly higher numbers of
CMFDA/CD11c cells at the tumor site (Fig. 1C). The effect of
DETA-NO was abrogated by ODQ. CMFDACD11c cells ac-
counted for 0.1% of the recovered cells and did not change signif-
icantly with the various treatments (not shown).
All NO effects were mimicked by 8-Br-cGMP and prevented by
ODQ, indicating that NO acts through cGMP. Indeed, treatment with
DETA-NO increased generation of cGMP. Values measured in the
first 30 min were 4.39  0.11, 0.55  0.07, and 0.69  0.08
pmol/mg/min in DETA-NO-treated DCs, controls, and DETA-NO-
plus ODQ-treated DCs, respectively (P 0.001 in DETA-NO-treated
cells versus control; n  4). The rate of cGMP generation did not
change significantly with time up to 2 h (not shown).
NO Protects DCs from Apoptosis Induced by B16-F1 Cells in a
cGMP-Dependent Manner. DC apoptosis is induced by tumor cells
through the paracrine release of as yet unidentified factors (4, 10, 14).
DCs cultured for 48 h in the presence of B16SN died via apoptosis, as
demonstrated by the appearance of a hypodiploid DNA peak and by
the decrease in the mitochondrial membrane potential (Fig. 2A).
Fig. 1. Treatment with nitric oxide (NO)/cGMP enhances dendritic cell (DC) antitumor
activity in vivo. C57BL/6 mice (5/group) received injections of 1  105 B16-F1 cells.
Vehicle or DCs (1  106 cells) treated for 2 h in the absence (UT DCs) or presence of
(z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO;
10 M), 8-Br-cGMP (3 mM), or DETA-NO plus H-(1,2,4)-oxadiazolo[4,3-]quinoxalin-
1-one (ODQ; 1 M) were injected at days 6, 12, 18, and 24. A, tumor size  SE (bars;
n  6); B, survival of animals (in one of six reproducible experiments). C, C57BL/6 mice
received injections of 1  105 B16-F1 cells. After 6 days, vehicle or 1  106 5-chlo-
romethylfluorescein (CMFDA)-loaded DCs treated for 2 h in the absence (UT DCs) or
presence of DETA-NO, 8-Br-cGMP, or DETA-NO plus ODQ were injected intratumor-
ally. Tumors were recovered after 24 and 72 h, and cells were dispersed, stained with
CD11c, and analyzed by flow cytometry. The values show the percentage  SE (bars) of
double-positive DCs (n  5). Statistical significance versus untreated DCs: , P  0.05;
, P  0.001.
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Treatment with DETA-NO resulted in significant (P  0.001; n  8)
protection of DCs, an action mimicked by 8-Br-cGMP and prevented
when the NO donor was administered together with ODQ (Fig. 2A).
In the absence of tumors, none of the treatments affected DC viability
(not shown). These results indicate that NO protects DCs from
B16SN-induced apoptosis in a cGMP-dependent manner.
NO/cGMP Inhibits DCs Apoptosis by Reversing the Effects of
B16SN on Activation of Caspase-9 and Expression of Members of
the Bcl-2 Family of Proteins. Exposure of DCs to B16SN caused an
increase in caspase-9 activity (Fig. 2B). Activation of caspase-9 was
crucial to tumor-induced DC apoptosis as shown by the effects of the
enzyme inhibitor Ac-LEHD-CHO (60 M), which reduced apoptosis
by 79.3  6.8% (P  0.001 versus control; n  5). Caspase-9
activation by B16SN was inhibited significantly (P  0.01; n  5) by
treatment of DCs with either 8-Br-cGMP or DETA-NO, but not with
DETA-NO plus ODQ (Fig. 2B). None of the treatments modified the
basal activity of caspase-9 (not shown).
Upstream of caspase-9, altered expression of Bax, Bcl-xL, and
Bcl-2 has been implicated in tumor-induced apoptosis of DCs (5, 10,
11, 14). Consistently, exposure of DCs for 48 h to B16SN resulted in
increased expression of Bax and reduced expression of Bcl-2 and
Bcl-xL (Fig. 2C). Treatment of DCs with DETA-NO reversed the
effects of B16SN on expression of Bax, Bcl-2, and Bcl-xL (by
89  4.9, 87  2.5, and 97  3.4%, respectively; P  0.001 in
DETA-NO-treated cells versus control; n  5). The effects of
DETA-NO were mimicked by 8-Br-cGMP and prevented by ODQ
(Fig. 2C). DETA-NO, 8-Br-cGMP, and ODQ had no effect on Bcl-2,
Bax, and Bcl-xL expression levels when administered alone (not
shown).
NO/cGMP Restores Mixed-Lymphocyte Reaction and Cyto-
toxic Functions of DCs Exposed to B16SN. DCs exert a direct
cytotoxic effect against tumor cells (16, 21). DCs exposed for 16 h to
B16SN displayed significantly reduced cytotoxicity against B16-F1
cells (Fig. 3A). DETA-NO restored DC cytotoxic activity. DCs did not
kill syngeneic splenocytes used as controls (not shown). DCs exposed
to tumors stimulate T-cell proliferation less efficiently (3, 14). Indeed,
DCs incubated for 16 h with B16SN showed a reduced capacity to
stimulate T cells in a mixed-lymphocyte reaction assay (Fig. 3B). DC
Fig. 2. Treatment with nitric oxide (NO) counteracts in a cGMP-dependent manner apoptogenic signals elicited in dendritic cells (DCs) by B16SN. DCs were treated for 2 h in the
absence (UT) or presence of (z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO; 10 M), 8-Br-cGMP (3 mM), or DETA-NO plus H-(1,2,4)-
oxadiazolo[4,3-]quinoxalin-1-one (ODQ; 1 M). The compounds were then removed, and DCs were exposed for 72 h to B16SN. A, evaluation by flow cytometry of the hypodiploid
DNA peak, measured after staining with propidium iodide (PI), or of the mitochondrial membrane potential, measured using the potential-sensitive mitochondrial dye tetramethyl-
rhodamine ethyl ester (TMRE). Results are from one of eight reproducible experiments. The numbers in the panels represent the percentage of fluorescence values  SE measured for
the eight experiments in the region indicated by the horizontal bars labeled M1. B, caspase-9 activity values are reported as the percentage  SE (bars) of those observed in untreated,
control DCs (11  0.1 pmol/min/mg; n  5). C, expression levels of Bcl-2, Bcl-xL, and Bax, revealed by immunoblotting. The panel shows one of five reproducible experiments.
Statistical significance versus B16SN-treated DCs: , P  0.01; , P  0.001.
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treatment with DETA-NO rescued the phenotype. The effects of NO
on both DC cytotoxic activity and their ability to activate T cells were
cGMP dependent because they were mimicked by 8-Br-cGMP and
were prevented when DETA-NO was added together with ODQ.
Discussion
In the present study, we showed that a brief ex vivo treatment of
DCs with NO increases their antitumor therapeutic efficacy. NO-
treated DCs not only reduced the growth of the highly tumorigenic
and poorly immunogenic B16 melanoma, but also caused tumor
regression and improved animal survival. In contrast, untreated DCs
disappeared from the tumor site and failed to cure any animals. The
action of NO was found to be persistent (brief exposure of DCs
yielded long-lasting antitumor action) and to depend on the generation
of cGMP after activation of guanylate cyclase, an enzyme activated by
physiological (nanomolar) concentrations of the gas (13, 15, 17, 18).
Thus, antitumor action was obtained with a short-term drug exposure,
compatible with minimal manipulation of DCs ex vivo, and with
concentrations of NO in the physiological range.
The antitumor action of NO/cGMP was associated with an in-
creased persistence of DCs in the tumor. This suggests that in vivo
DCs were protected against tumor-induced apoptosis. This conclusion
is supported by in vitro experiments showing that a brief pulse with
NO increases DCs resistance to the apoptogenic effects of the tumor
environment. NO inhibited the tumor-induced reduction of the mito-
chondrial membrane potential and activation of caspase-9 and re-
stored the expression levels of Bcl-2, Bax, and Bcl-xL, which are
altered in tumor-exposed DCs (4, 5, 10, 11, 14). This, together with
the observation that the NO action persists after its removal, strongly
suggests that NO switches off the entire apoptotic program triggered
by tumors in DCs rather than acting as a simple negative modulator of
selected apoptotic signals. This explains the efficacy and the persist-
ence of the protective action of NO. We found two additional effects
of NO that might contribute to its antitumor effect. NO prevented the
tumor-induced impairment of both DC cytotoxic activity and the
ability of DCs to stimulate T-cell proliferation. Of importance, all of
the in vitro effects of NO were found to depend on generation of
cGMP, consistent with the cGMP dependence of its effects in vivo.
The treatment of DCs we propose does not require extensive cell
manipulation, is not toxic, and appears worth pursuing in view of the
new NO donors and compounds able to increase cGMP concentration
undergoing validation for clinical use at present (22). Because of its
simplicity, the treatment might be easily combined with other strate-
gies to yield an enhanced therapeutic effect combining increased DC
survival and efficacy in eliciting antitumor immune responses.
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